Treatment of latent HIV-1 infections using auranofin or arsenic trioxide

摘要

An oxidative stress inducer for use in the treatment of a latent human immunodeficiency virus type 1 (HIV-1) infection, wherein said oxidative stress inducer is auranofin or arsenic oxide which is As2O3 or As4O6; where auranofin or arsenic oxide induces the activation of HIV-1 from quiescence and is an epigenetic modulator; and where the treatment also includes antiretroviral therapy